Aptevo Therapeutics Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Aptevo Therapeutics Inc. has filed an S-1/A amendment, indicating ongoing efforts related to securities registration.</b>

AI Summary

Aptevo Therapeutics Inc. (APVO) filed a Amended IPO Registration (S-1/A) with the SEC on March 29, 2024. Aptevo Therapeutics Inc. filed an S-1/A amendment on March 29, 2024. The filing is a registration statement under the Securities Act of 1933. The company's principal executive offices are located at 2401 4th Ave., Suite 1050, Seattle, WA 98121. Marvin L. White is listed as President and Chief Executive Officer. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

For investors and stakeholders tracking Aptevo Therapeutics Inc., this filing contains several important signals. This amendment suggests the company is actively pursuing capital raising or other securities-related transactions. The filing provides updated corporate and contact information, crucial for investors and regulatory oversight.

Risk Assessment

Risk Level: low — Aptevo Therapeutics Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate significant new risks or positive developments.

Analyst Insight

Monitor future filings for details on the purpose of the S-1/A amendment, such as an upcoming offering or other corporate actions.

Key Numbers

• 333-278103 — Registration Number (Securities Act of 1933 Registration Number)
• 2834 — SIC Code (Primary Standard Industrial Classification Code)
• 81-1567056 — IRS Number (I.R.S. Employer Identification Number)
• 2024-03-29 — Filing Date (Date of filing)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant Name
• Marvin L. White (person) — President and Chief Executive Officer
• Sean M. Donahue (person) — Copies to counsel
• Paul Hastings LLP (company) — Counsel
• SoYoung Kwon (person) — Senior Vice President and General Counsel
• Charles E. Phillips (person) — Copies to counsel
• Ellenoff Grossman & Schole LLP (company) — Counsel
• 206-838-0500 (dollar_amount) — Business Phone Number

FAQ

Industry Context

Aptevo Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for specific details regarding the purpose of the amendment.
2. Track future SEC filings from Aptevo Therapeutics for updates on their securities offerings or corporate actions.
3. Analyze the company's business strategy and financial health in conjunction with this filing.

Key Dates

• 2024-03-29: Filing of S-1/A Amendment — Indicates an active step in the company's securities registration process.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating a continuation or modification of an ongoing process rather than a new filing.

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (common stock) together with
• $5.42 — sumed combined public offering price of $5.42 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $100,000 — cement agent fee, will be approximately $100,000. The delivery of the shares of common

Filing Documents

• apvo-2024-s1a.htm (S-1/A) — 849KB
• apvo-ex5_1.htm (EX-5.1) — 31KB
• apvo-ex23_1.htm (EX-23.1) — 4KB
• img57496738_0.jpg (GRAPHIC) — 8KB
• img135455931_0.jpg (GRAPHIC) — 7KB
• img135455931_1.jpg (GRAPHIC) — 58KB
• img135455931_2.jpg (GRAPHIC) — 516KB
• img135455931_3.jpg (GRAPHIC) — 4KB
• 0000950170-24-038743.txt (&nbsp;) — 1702KB

USE OF PROCEEDS

USE OF PROCEEDS 10 CAPITALIZATION 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 14

description of securities we are offering

description of securities we are offering 19 PLAN OF DISTRIBUTION 23 I ncorporation of certain information by reference 26 WHERE YOU CAN FIND MORE INFORMATION 26 LEGAL MATTERS 27 EXPERTS 27 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &#x201c; Where You Can Find More Information.&#x201d; You should carefully read this prospectus as well as additional information described under &#x201c; Incorporation of Certain Information by Reference ,&#x201d; before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have bee

View Full Filing

View this S-1/A filing on SEC EDGAR